NASDAQ:PRTA Prothena Q2 2025 Earnings Results & Report $8.49 +0.12 (+1.43%) As of 12:43 PM Eastern This is a fair market value price provided by Massive. Learn more. Prothena missed analyst expectations on both earnings and revenue in its Q2 2025 results, released August 4, 2025. The company reported EPS of -$1.86 versus the -$1.11 consensus estimate, while revenue of $4.42 million fell short of the $5.36 million estimate by $0.94 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 4, 2025TimeAfter Market ClosesConference Call4:00 PM ET Prothena EPS ResultsActual EPS-$1.86Consensus EPS -$1.11Beat/MissMissed by -$0.75One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersProthena Revenue ResultsActual Revenue$4.42 millionExpected Revenue$5.36 millionBeat/MissMissed by -$943.00 thousandYoY Revenue GrowthN/AUpcoming EarningsProthena's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Prothena Q2 2025 Earnings FAQ Did Prothena beat earnings estimates for Q2 2025? Prothena (NASDAQ:PRTA) reported earnings of -$1.86 per share for Q2 2025, missing the consensus estimate of -$1.11. The report was announced on Monday, August 4, 2025. What was Prothena's revenue for Q2 2025? Prothena reported revenue of $4.42 million for Q2 2025, against a consensus estimate of $5.36 million. When is Prothena's next earnings date? Prothena's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Prothena on the company's earnings history page. Prothena Earnings HeadlinesProthena Corporation plc (PRTA) - What Are Brokerages Saying About This Stock?October 13 at 4:29 AM | americanbankingnews.comInsider Buying: Prothena (NASDAQ:PRTA) Major Shareholder Purchases $771,300.00 in StockOctober 12 at 4:09 AM | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 15 at 1:00 AM | Stansberry Research (Ad)Prothena (NASDAQ:PRTA) Major Shareholder Purchases $1,050,000.00 in StockOctober 12 at 4:08 AM | americanbankingnews.comProthena (NASDAQ: PRTA) insider buys $1.82 million of shares, lifts stakeOctober 12 at 3:02 AM | americanbankingnews.comKyntra Bio (NASDAQ:KYNB) & Prothena (NASDAQ:PRTA) Head to Head SurveyOctober 9, 2026 | americanbankingnews.comSee More Prothena Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prothena? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prothena and other key companies, straight to your email. Email Address About ProthenaProthena (NASDAQ:PRTA) is a clinical-stage biotechnology company focused on discovering and developing therapies for diseases caused by protein misfolding or abnormal protein accumulation. Its research programs target neurological and systemic disorders, including Alzheimer’s disease, Parkinson’s disease, and transthyretin amyloidosis. The company’s pipeline has included PRX012, an investigational next-generation antibody targeting amyloid beta for Alzheimer’s disease; prasinezumab, an anti-alpha-synuclein antibody being developed for Parkinson’s disease through a collaboration with Roche; and birtamimab, an investigational treatment designed to target misfolded light chains associated with AL amyloidosis. These candidates remain subject to clinical testing and regulatory review, and Prothena does not have a broad portfolio of commercially marketed products. Prothena was established in 2012 following the separation of neuroscience assets from Elan Corporation. The company is incorporated in Ireland and conducts research and development through operations and partnerships serving international markets. Its business model centers on applying expertise in protein biology and antibody development to create potential treatments for serious diseases with limited therapeutic options.View Prothena ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling?UnitedHealth Beats on Earnings, But Investors Question Growth PathIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
